{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Invasive+Carcinoma+of+the+Breast&page=12", "query": { "condition": "Invasive Carcinoma of the Breast", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 351, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Invasive+Carcinoma+of+the+Breast&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Invasive+Carcinoma+of+the+Breast&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T21:53:30.619Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Invasive Breast Lobular Carcinoma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 138, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT04115306", "title": "Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "PMD-026", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Phoenix Molecular Designs", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2019-11-14", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 10, "location_summary": "Gilbert, Arizona • Duarte, California • Irvine, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04115306" }, { "nct_id": "NCT02282345", "title": "Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Deleterious BRCA1 Gene Mutation", "Deleterious BRCA2 Gene Mutation", "HER2/Neu Negative", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-04-16", "completion_date": "2022-06-07", "has_results": true, "last_update_posted_date": "2022-07-06", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282345" }, { "nct_id": "NCT03113825", "title": "Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Invasive Malignant Neoplasm of Female Breast", "Carcinoma Breast", "Breast Cancer Female", "Carcinoma, Ductal, Breast", "Stage II Breast Cancer", "Stage I Breast Cancer", "Stage III Breast Cancer" ], "interventions": [ { "name": "Investigational Imaging device", "type": "DEVICE" }, { "name": "AVB-620", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "Avelas Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 92, "start_date": "2017-07-05", "completion_date": "2020-11-18", "has_results": false, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 13, "location_summary": "San Diego, California • Washington D.C., District of Columbia • Jacksonville, Florida + 10 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Barrington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03113825" }, { "nct_id": "NCT04622319", "title": "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-Positive Primary Breast Cancer", "Residual Invasive Breast Cancer" ], "interventions": [ { "name": "DS-8201a", "type": "DRUG" }, { "name": "T-DM1", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1600, "start_date": "2020-12-04", "completion_date": "2028-06-20", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 126, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04622319" }, { "nct_id": "NCT07806630", "title": "SHORTened Duration of TAMoxifen", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Risk for Invasive Breast Cancer" ], "interventions": [ { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Tamoxifen (Nolvadex)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 250, "start_date": "2026-09-01", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07806630" }, { "nct_id": "NCT00527293", "title": "Partial Breast Radiation Therapy in Treating Women Undergoing Breast-Conserving Therapy for Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "3-dimensional conformal radiation therapy", "type": "RADIATION" }, { "name": "brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 29, "start_date": "2007-06", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-08-25", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 4, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00527293" }, { "nct_id": "NCT00064311", "title": "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "ravuconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-06", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00064311" }, { "nct_id": "NCT04532177", "title": "Stereotactic Body Radiation Therapy (SBRT) for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2020-08-19", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04532177" }, { "nct_id": "NCT00253383", "title": "Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "counseling intervention", "type": "OTHER" }, { "name": "educational intervention", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 329, "start_date": "2003-01", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2014-12-19", "last_synced_at": "2026-10-13T21:53:30.619Z", "location_count": 2, "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont", "locations": [ { "city": "Lebanon", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253383" } ] }